Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin
Open Access
- 21 May 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in Brain
- Vol. 132 (4) , 919-932
Abstract
Huntington disease is a neurodegenerative disorder caused by an expanded CAG repeat in the Huntington disease gene. The symptomatic phase of the disease is defined by the onset of motor symptoms. However, psychiatric disturbances, including depression, are common features of Huntington disease and recent studies indicate that depression can occur long before the manifestation of motor symptoms. The aetiology of depression in Huntington disease is not fully understood and psychosocial factors such as the knowledge of carrying a mutation for an incurable disease or adverse social circumstances may contribute to its presentation. Due to the difficulties in discriminating between social and biological factors as contributors to depression in clinical Huntington disease, we chose to assess whether a model for Huntington disease not subject to environmental stressors, namely the YAC mouse model of Huntington disease, displays a depressive phenotype. Indeed, the YAC transgenic mice recapitulate the early depressive phenotype of Huntington disease as assessed by the Porsolt forced swim test as well as the sucrose intake test as a measure of anhedonia. The YAC model mirrors clinical Huntington disease in that there were no effects of CAG repeat length or disease duration on the depressive phenotype. The depressive phenotype was completely rescued in YAC transgenic animals expressing a variant of mutant huntingtin that is resistant to cleavage at amino acid 586 suggesting that therapies aimed towards inhibition of huntingtin cleavage are also likely to have beneficial effects on this aspect of the disease. In conclusion, our study provides strong support for a primary neurobiological basis for depression in Huntington disease.Keywords
This publication has 85 references indexed in Scilit:
- A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's diseaseJournal of Experimental Medicine, 2008
- Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's diseaseNeurobiology of Disease, 2008
- Behavioural problems in Huntington's disease using the Problem Behaviours AssessmentGeneral Hospital Psychiatry, 2008
- Depression after status epilepticus: behavioural and biochemical deficits and effects of fluoxetineBrain, 2008
- Corticostriatal synaptic function in mouse models of Huntington's disease: early effects of huntingtin repeat length and protein loadThe Journal of Physiology, 2007
- Psychiatric disorders in preclinical Huntington's diseaseJournal of Neurology, Neurosurgery & Psychiatry, 2007
- Neuroplasticity Mediated by Altered Gene ExpressionNeuropsychopharmacology, 2007
- New insights into BDNF function in depression and anxietyNature Neuroscience, 2007
- Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington diseaseExperimental Neurology, 2005
- Molecular analysis and clinical correlations of the Huntington's disease mutationThe Lancet, 1993